GIGA-564
- Generic Name
- GIGA-564
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- GigaGen, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06258304
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath